Nice | Prostate cancer

30th January 2014 by Louise Hudman


This updated guideline from Nice on prostate cancer has a couple of useful elements for us. The first is that they have standardised the protocol for ‘active surveillance’ and GPs are expected to be involved in the PSA monitoring aspect – so that is worth having a look at. The second aspect is about managing some of the side-effects of treatments.

Active surveillance

Patients with ‘low-risk’ cancers (ie those that are less likely to go on to cause further problems) and those with ‘intermediate-risk’ cancers who opt for it, can choose active surveillance. They are monitored with regular PSA, DRE (digital rectal exam) and biopsy. NICE encourages the use of GPs in the PSA monitoring aspect. They found that different centers around the country were doing very different things, so they have attempted to standardise what is done. This is based on expert consensus as trial evidence is lacking. ‘PSA kinetics’ means the speed of change (which we don’t need to worry about).

Side-effects of treatments

Read for free

Sign up to access everything.

Three-month free trial


Already a member? Login to view this content.


"I think the Spip and Cudos tool both have a very positive future and fulfil a real need."

Dr Amy Kerstein

See the full list of features within our NASGP membership plans